胰臟癌新療法展現潛力
New Treatment Shows Promise for Pancreatic Cancer
數十年來，胰臟癌常被視為令人束手無策的疾病，通常被認為是一種幾乎等同於絕症的診斷。
For decades, pancreatic cancer has been viewed with a sense of helplessness, often termed an almost automatic terminal diagnosis.
近期的重大突破正在挑戰現狀，其中兩款新藥引領風騷。
Recent breakthroughs are challenging the status quo, with two new drugs leading the way.
Daraxonrasib透過標靶長期被認為「無法藥物治療」的頑固KRAS突變，顯示出能將中位存活率提升近一倍的驚人功效。
Daraxonrasib has shown a remarkable ability to nearly double median survival rates by targeting the elusive KRAS mutation, long considered 'undruggable.'
與此同時，Elraglusib則透過分解圍繞在腫瘤周圍那層緻密的保護網，使化療能更有效地觸及癌細胞，從而改變了治療格局。
Meanwhile, Elraglusib is changing the game by breaking down the dense, protective web surrounding tumors, allowing chemotherapy to reach cancer cells more effectively.
除此等治療外，研究人員正探索「癌症攔截」，目標是在癌前病變演變成完全的腫瘤之前將其消除。
Beyond these treatments, researchers are exploring 'cancer interception,' which aims to eliminate precancerous lesions before they ever become full-blown tumors.
透過拋棄「一體適用」的方法，轉而採取針對每個腫瘤獨特基因組成的個人化醫療，科學家們正開始將胰臟癌視為一種可控的狀況。
By moving away from a one-size-fits-all approach toward personalized medicine—focusing on the unique genetic profile of each tumor—scientists are beginning to view pancreatic cancer as a manageable condition.
儘管挑戰依然存在，但這些發展提供了謹慎樂觀的動力，讓我們終於邁入為全球患者帶來更多希望的新時代。
While challenges remain, these developments provide a significant boost of cautious optimism that we are finally entering a new, more hopeful era for patients worldwide.
